Stents Move Up to the Carotid

Just as drug-eluting stents prevent heart attacks by maintaining the patency of coronary arteries, so do carotid artery stents prevent strokes by keeping carotid arteries open. Carotid artery stenting, like coronary stenting, is a minimally invasive, percutaneous procedure and both procedures use similar kinds of devices. The large cardiovascular device companies are all in clinical trials with carotid artery stents, but none is expected on the US market before 2005. Still, the market for carotids isn't likely to be nearly as big as that of coronary stents.

If drug-eluting stents are the Next Big Thing in interventional clinical practice, then carotid stents may be Another Big Thing. Even as their primary focus remains developing drug-eluting stents, the large cardiovascular device companies are progressing with clinical trials of carotid artery stents. The application of stents in the carotid artery may prove to be as effective in preventing strokes as coronary stents have been (and their progeny, drug-eluting stents, appear to be) at preventing heart attacks. For coronary stents, this is accomplished by maintaining the patency of coronary arteries. In the case of carotid artery stents, the key is to keep the carotid artery, the primary blood vessel leading to the brain, free of obstructions caused largely by atherosclerotic plaque build-up.

Carotid artery and coronary artery stenting share some things in common—they are minimally invasive, percutaneous procedures using similar kinds of...

More from Innovation

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.